repriorit streamlin i/o pipelin pt
wednesday aduro announc strateg repriorit pipelin shift
resourc focu develop sting modul anti-april program
de-emphasize develop pladd sever preclin asset
repriorit come staf reduct translat reduc
cash burn extend aduro oper runway earli believ
decis reflect manag confid sting april program
slate deliv new clinic data year given earli sign
clinic activ shown addit clinic data expect
believ aduro neg ev unjustifi remov pladd program
estim lower pt reiter outperform
aduro depriorit develop sever program includ pladd
antibodi anti-sirp antibodi
shift primari focu sting modul compani
sting program attract signific licens agreement novarti
oncolog focus inflammatori auto-immun diseas
remind pladd clinical-stag person neoantigen-target
vaccin colorect cancer aduro previous present encourag earli
clinic data demonstr vaccin abil stimul t-cell respons
specul highli person natur pladd may translat
intract expens manufactur aduro shoulder without partner
view spark object activ demonstr
monotherapi
edg
intratumor therapi discount investor recently-
publish preclin work could inform optim dose strategi cell rep
expect see dose escal result
monotherapi in-combin spartalizumab
solid
believ could find applic multipl indic includ iga
nephropathi igan multipl myeloma mm phase trial
treatment relapsed/refractori mm on-going believ initi data
dose escal cohort could also present late separ
aduro plan initi phase trial igan
aduro announc end cash well
current market capit exclud up-front receiv lilli
collabor revis forward estim reflect expect
reduct oper expens due strateg repriorit
remov pladd sum-of-th part valuat contribut per
share npv
year price histori
immunotherapi compani focus
commerci novel therapi
analyst certif import disclosur see disclosur
approv peak sale us eu
approv anti-april antibodi peak sale us
eu
earlier anticip trial result regulatori approv
success develop sting modul addit
potenti mileston payment merck develop
assign outperform rate month
price target base convict compani
success develop commerci sever
clinical-stag program current ascrib valu two
program melanoma anti-april antibodi
multipl myeloma believ could
achiev regulatori approv late po
could approv po
potenti present updat data phase trial combin
spartalizumab
potenti present interim phase result
mm
failur anti-april
termin co-develop co-commerci
partnership novarti
termin merck partnership potenti creat neg
month price target per share deriv risk-adjust sum-of-the-part npv valuat aduro
per share contribut probabl success anti-april program per share contribut po
includ project net cash contribut per share round arriv price target
risk includ clinic regulatori competit market price pressur partnership risk
note stock trade may consid specul appropri risk-toler investor
multipl tumor
potenti initi phase combin trial ipilimumab melanoma
potenti present updat data phase trial combin spartalizumab
potenti initi phase combin trial trial head neck cancer
multipl myeloma
potenti present interim dose escalation/dos expans result phase studi
iga nephropathi
potenti initi phase trial
compani present oppenheim co
updat valuat aduro remov contribut pladd
program colorect cancer continu valu use probability-
weight sum-of-the-part npv methodolog summar exhibit model
includ contribut two differ program treatment
solid tumor metastat melanoma probabl success
regulatori approv commerci launch anti-april
antibodi treatment relapsed/refractori multipl myeloma po
regulatori approv commerci launch expect compani
end cash posit last includ project cash
posit per share arriv price target round
figur thousand except per share licens expens good sold research develop gener administr intang oper loss incom expens gain loss remeasur fair valu warrant interest incom expens incom expens total incom expens loss incom incom tax benefit incom per share share outstand comark breidenbach outperform
figur thousand except per share asset cash market tax expens current current market equip asset cash assetsoth assetstot stockhold equitycurr liabil account clinic trial manufactur expens current tax long term equiti common paid-in comprehens incom stockhold liabil stockhold comark breidenbach aduro
stock price compani mention report
